ProNAi Therapeutics (NASDAQ:DNAI) : Zacks Investment Research ranks ProNAi Therapeutics (NASDAQ:DNAI) as 2, which is a Buy recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2.5, which indicates as a Buy.
ProNAi Therapeutics (NASDAQ:DNAI) : The highest level ProNAi Therapeutics (NASDAQ:DNAI) is projected to reach is $35 for the short term and the lowest estimate is at $3. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $11.63 and the possibility the share price can swing is $15.6.
Company shares have received an average consensus rating of Hold for the current week Also, Equity analysts at the Brokerage firm Jefferies downgrades its rating on ProNAi Therapeutics (NASDAQ:DNAI). The rating major has initiated the coverage with hold rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on June 6, 2016.
ProNAi Therapeutics (NASDAQ:DNAI): stock turned positive on Tuesday. Though the stock opened at $1.9, the bulls momentum made the stock top out at $2.0298 level for the day. The stock recorded a low of $1.89 and closed the trading day at $1.99, in the green by 5.85%. The total traded volume for the day was 943,326. The stock had closed at $1.88 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Chapman Wendy, officer (SVP Clinical Operations) of Pronai Therapeutics Inc, had unloaded 3,000 shares at an average price of $7.01 in a transaction dated on March 22, 2016. The total value of the transaction was worth $21,030.
ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Companys lead DNAi product candidate, PNT2258, treat cancers that overexpress BCL2, an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine, a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.